Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 | Q9Y3Q4 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cilobradine SCHEMBL1855245 | 1.00 | HCN4 (0.57) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| Cilobradine SCHEMBL30169956 | 1.00 | HCN4 (0.57) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| Cilobradine SCHEMBL2459609 | 0.99 | CYP3A4 (0.58) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| Cilobradine SCHEMBL9740702 | 0.99 | HCN4 (0.56) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| Cilobradine SCHEMBL29896706 | 0.99 | CYP3A4 (0.58) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| Cilobradine SCHEMBL9518220 | 0.99 | CYP3A4 (0.58) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| Hydrochloric Acid SCHEMBL9739678 | 0.96 | CYP3A4 (0.57) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| SCHEMBL9740314 | 0.96 | HCN4 (0.53) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| SCHEMBL9739258 | 0.95 | DHCR7 (0.57) | HCN4MAPTCYP3A4ALOX15DHCR7 | |
| SCHEMBL9742193 | 0.95 | HCN4 (0.52) | HCN4MAPTCYP3A4ALOX15DHCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195525-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-06-19 | — | — | US | claimed |
| WO-2025125409-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-06-19 | — | — | WO | claimed |
| US-20230270693-A1 | Molecular Targets for Modulation of Dissociative and Associative States | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-08-31 | — | — | US | claimed |
| EP-4087469-A1 | DEVICES AND METHODS FOR TREATING CANCER AND CARDIAC WASTING | Nazzano Devices Limited (IE) | 2022-11-16 | — | — | EP | claimed |
| US-20220347150-A1 | TASIMELTEON USE IN TREATING SLEEP ABERRATIONS | VANDA PHARMACEUTICALS INC. | 2022-11-03 | — | — | US | claimed |
| CN-114641284-A | Application of tasimelteon in treatment of abnormal sleep | 万带兰制药公司 | 2022-06-17 | — | — | CN | claimed |
| EP-3989964-A1 | TASIMELTEON USE IN TREATING SLEEP ABERRATIONS | Vanda Pharmaceuticals Inc. (US) | 2022-05-04 | — | — | EP | claimed |
| WO-2022035773-A1 | MOLECULAR TARGETS FOR MODULATION OF DISSOCIATIVE AND ASSOCIATIVE STATES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-17 | — | — | WO | claimed |
| EP-3810184-A2 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | University of Rochester (US) | 2021-04-28 | — | — | EP | claimed |
| CN-112654366-A | Methods of treating or inhibiting the onset of huntington's disease | 罗切斯特大学 | 2021-04-13 | — | — | CN | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040138306-A1 | Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | US | claimed |
| US-20040014795-A1 | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-22 | — | — | US | claimed |
| EP-1362590-B1 | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-01-07 | — | — | EP | claimed |
| EP-1362590-A1 | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-11-19 | — | — | EP | claimed |
| CN-1422153-A | Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-04 | — | — | CN | claimed |
| EP-1276476-A2 | USE OF BRADYCARDIAC SUBSTANCES IN THE TREATMENT OF MYOCARDIAL DISEASES ASSOCIATED WITH HYPERTROPHY AND NOVEL MEDICAMENT COMBINATIONS | Boehringer Ingelheim Pharma KG (DE) | 2003-01-22 | — | — | EP | claimed |
| WO-2001078699-A2 | USE OF BRADYCARDIAC SUBSTANCES IN THE TREATMENT OF MYOCARDIAL DISEASES ASSOCIATED WITH HYPERTROPHY AND NOVEL MEDICAMENT COMBINATIONS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195525-A1 | ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS | AGTR1, AGTR2, EDNRA | HCN4 2921/4885MAPT 3374/4885CYP3A4 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.